What NEXTBio Capital Management LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2038158 · Filed Nov 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 3.7M |
| ±0% |
| $25.4M |
| 10.8% |
CMPSCOMPASS Pathways plc | 1.8M | ±0% | $22.1M | 9.4% |
RYTMRhythm Pharmaceuticals, Inc. | 131.8K | ±0% | $12.5M | 5.4% |
VORVor Biopharma Inc. | 620.9K | −30.2% | $11.8M | 5.1% |
PHVSPharvaris N.V. | 372.6K | +244.8% | $11.8M | 5% |
XENEXenon Pharmaceuticals Inc. | 310.2K | +69.3% | $11.5M | 4.9% |
ZBIOZenas BioPharma, Inc. | 426.7K | ±0% | $11.5M | 4.9% |
PVLAPalvella Therapeutics, Inc. | 80.4K | −10.6% | $11.1M | 4.7% |
GPCRStructure Therapeutics Inc. | 312.5K | ±0% | $9.8M | 4.2% |
ORICOric Pharmaceuticals, Inc. | 684.5K | −3.1% | $9.2M | 3.9% |
ENTXEntera Bio Ltd. | 2.9M | New | $8.5M | 3.6% |
VSTMVerastem, Inc. | 906.7K | −30.6% | $7.3M | 3.1% |
IVAInventiva S.A. | 1.8M | ±0% | $6.6M | 2.8% |
ZLABZai Lab Ltd | 238.4K | +30.0% | $6.3M | 2.7% |
PCVXVaxcyte, Inc. | 107.2K | ±0% | $6.1M | 2.6% |
COGTCogent Biosciences, Inc. | 178K | +35.8% | $5.7M | 2.4% |
KRSAKorsana Biosciences, Inc. | 175.4K | New | $5.6M | 2.4% |
CBIOCrescent Biopharma, Inc. | 372.9K | ±0% | $5.4M | 2.3% |
BLSMBlossomHill Therapeutics, Inc. | 250K | New | $4.7M | 2% |
IRONDisc Medicine, Inc. | 52.7K | ±0% | $3.4M | 1.5% |
LBRXLB Pharmaceuticals Inc | 69.5K | +1.9% | $2.7M | 1.1% |
ADRXADARx Pharmaceuticals, Inc. | 100K | New | $2M | 0.9% |
GLUEMonte Rosa Therapeutics, Inc. | 111.5K | New | $1.3M | 0.6% |
EVMNEvommune, Inc. | 119.1K | ±0% | $983.5K | 0.4% |